In patients with acute coronary syndrome(ACS)or undergoing percutaneous coronary intervention(PCI),pharmacological blockade of the platelet glycoprotein Ⅱ b/Ⅲ a receptor inhibitor has emerged as a key strategy for improving clinical outcome.

Platelet GPⅡb/Ⅲa inhibitors in neurointervention therapeutics;

The novel platelet GP Ⅱb/Ⅲa receptor antagonist——tirofiban hydrochloride;